Verona Pharma PLC Holding(s) in Company (6427E)
May 09 2017 - 10:36AM
UK Regulatory
TIDMVRP
RNS Number : 6427E
Verona Pharma PLC
09 May 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or Verona Pharma plc
the underlying issuer
of existing shares to which
voting rights are
attached:
------------------------------------------------------------- ------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
---------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
----------------------------------------------------------------- --------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
----------------------------------------------------------------- --------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
----------------------------------------------------------------- --------------------------------
An event changing the breakdown of voting rights
----------------------------------------------------------------- --------------------------------
Other (please
specify):
--------------------------------------------------------- ------ --------------------------------
3. Full name of person(s) Abingworth LLP
subject to the Abingworth Bioventures VI
notification obligation: LP
----------------------------------------------------------- --------------------------------------
4. Full name of shareholder(s) State Street (Nominees) Limited
(if different from 3.): (as nominee for Abingworth
Bioventures V LP)
----------------------------------------------------------- --------------------------------------
5. Date of the transaction 3 May 2017
and date on
which the threshold is
crossed or
reached:
----------------------------------------------------------- --------------------------------------
6. Date on which issuer 5 May 2017
notified:
----------------------------------------------------------- --------------------------------------
7. Threshold(s) that is/are Upward crossing of the 7%,
crossed or threshold
reached:
----------------------------------------------------------- --------------------------------------
8. Notified details: Abingworth LLP
----------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
----------------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
-------------- -------------------------------- --------------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights
Shares Voting rights
Rights
-------------- --------------- --------------- ---------------------- --------------------- ---------------------------
Direct Direct Indirect Direct Indirect
-------------- ----------- ----------- ---------------------- --------- ---------- ------------ -------------
Verona Pharma
plc 3,510,553 3,510,553 3,510,553 0 3,510,553 0 3.55%
GB00B06GSH43
5p Ords
--------------- --------------- ------------ ------------------- ---------- -------------- -----------
Verona Pharma
plc
US9250501064
ADSs 3,705,000 0 3,705,000 0 3.74%
-------------- --------------- --------------- ------------ ------------------- ---------- -------------- -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
Period may be
acquired if
the
instrument
is
exercised/
converted.
------------------ ------------- --------------------------------------- ----------------------- -----------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights
instrument period refers to
---------------- ------------- ------------- ------------------------ ----------------------- -------------------------
Nominal Delta
---------------- ------------- ------------- ------------------------ ----------------------- -------------- ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
-------------------------------------------------- ------------------------------------------------------------------------
7,215,553 7.29%
-------------------------------------------------- ------------------------------------------------------------------------
8. Notified details: Abingworth Bioventures VI LP
-----------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
-----------------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
-------------- -------------------------------------------- ---------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights
Shares Voting rights
Rights
-------------- ----------------- ------------------------- ------------ ----------------------- ------------------------
Direct Direct Indirect Direct Indirect
-------------- ----------- ----------- -------- ------------ ------------ --------- ------------ ----------
Verona Pharma
plc 3,510,553 3,510,553 3,510,553 3,510,553 0 3.55% 0
GB00B06GSH43
5p Ords
--------------- ------------------------- ------------ -------------- --------- ------------ ----------
Verona Pharma
plc
US9250501064
ADSs 3,705,000 3,705,000 0 3.74 0
-------------- --------------- ------------------------- ------------ -------------- --------- ------------ ----------
B: Qualifying Financial Instruments
-----------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
Period may be
acquired if
the
instrument
is
exercised/
converted.
------------------ --------------- --------------------------------------- ------------------------- --------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
-----------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights
instrument period refers to
---------------- --------------- ------------- ------------------------ ------------------------- ----------------------
Nominal Delta
---------------- --------------- ------------- ------------------------ ------------------------- ---------- ----------
Total (A+B+C)
-----------------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------------------------------------------------------ ---------------------------------------------------
7,215,553 7.29%
------------------------------------------------------------------------ ---------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
-----------------------------------------------------------------------------------------------------------------------------
Abingworth Bioventures VI LP (which holds 7,215,553
shares in the company (7.29%)) is managed by Abingworth
LLP.
Proxy Voting:
-----------------------------------------------------------------------------------------------------------------------------
10. Name of the proxy holder:
---------------------------------------------------------------------------------------- -----------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
---------------------------------------------------------------------------------------- -----------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
---------------------------------------------------------------------------------------- -----------------------------------
13. Additional information:
------------------------------------------------------------------------ ---------------------------------------------------
14. Contact name: John Heard
------------------------------------------------------------------------ ---------------------------------------------------
15. Contact telephone number: 020 7534 1500
------------------------------------------------------------------------ ---------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUGUAWAUPMGCB
(END) Dow Jones Newswires
May 09, 2017 10:36 ET (14:36 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
